LFST
LifeStance Health Group, Inc.
LFST has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
LFST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
LFST's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LFST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $14.15 | — |
| Current | 74x | $14.15 | — |
| Cheap | 95x | $17.99 | +27% |
| Fair | 128x | $24.39 | +72% |
| Expensive | 319x | $60.61 | +328% |
Historical ranges are pointers, not guarantees.
LFST has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LFST Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
LFST has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LFST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | +39% |
| Q3 2026 | $0.19 | +$0.21 |
| Q2 2026 | $0.13 | +$0.17 |
| Q1 2026 | $0.06 | +$0.15 |
| Q4 2025 | $0.02 | +$0.17 |
LFST has returned to profit: it earned $0.19 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
LFST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $455.9M | +25% |
| Q2 2026 | $435.4M | +26% |
| Q1 2026 | $403.5M | +21% |
| Q4 2025 | $382.2M | +17% |
| Q3 2025 | $363.8M | +16% |
| Q2 2025 | $345.3M | +11% |
| Q1 2025 | $333M | +11% |
| Q4 2024 | $325.5M | +16% |
LFST has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +5.2 points |
| Q2 2026 | 7% | +7.9 points |
| Q1 2026 | 5.5% | +5 points |
| Q4 2025 | 4.7% | +4.4 points |
| Q3 2025 | 2% | +2 points |
| Q2 2025 | -0.8% | +4.3 points |
| Q1 2025 | 0.5% | +6.1 points |
| Q4 2024 | 0.3% | +12 points |
LFST's operating margin was 7.3% last quarter, up 5.2 points from the same quarter a year ago, near the top of its range since 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LFST on profitability, with a higher operating margin.
LFST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $22.4M | +32% |
| Q2 2026 | $87.9M | +55% |
| Q1 2026 | $22.3M | +$32.6M |
| Q4 2025 | $46.6M | -17% |
| Q3 2025 | $17M | -3.8% |
| Q2 2025 | $56.6M | +45% |
| Q1 2025 | -$10.3M | +$16.7M |
| Q4 2024 | $56M | +941% |
LFST has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
LFST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +3.9M shares |
| 1 year | +0.6% | +2.3M shares |
| 3 years | +4.7% | +17.6M shares |
LFST has 391M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.8M |
| Q2 2026 | $48.5M |
| Q1 2026 | $49.1M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LFST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LFST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 5.5x | High |
| Q4 2024 | 14.6x | High |
LFST has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LFST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.6 | Overbought |
| Stochastic | 75.0 | Neutral |
LFST's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LFST PE vs Healthcare Sector
| Metric | LFST | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 188% above |
| PE % | 3 | 37 | 34 pts below |
LFST is trading at 74x earnings, a 188% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over LFST on valuation relative to its sector.
LFST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.8 | 11% above |
| 20 week MA | $12.2 | 16% above |
| 50 week MA | $9.22 | 53% above |
| 100 week MA | $7.67 | 84% above |
| 200 week MA | $7.24 | 95% above |
LFST has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LFST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $10.1 | -58% |
| 2022 | $10.1 | $4.62 | -54% |
| 2023 | $4.62 | $7.83 | +69% |
| 2024 | $7.83 | $7.49 | -4.3% |
| 2025 | $7.49 | $7.13 | -4.8% |
| 2026 YTD | $7.13 | $14.2 | +98% |
LFST has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.